JP2022520998A5 - - Google Patents

Info

Publication number
JP2022520998A5
JP2022520998A5 JP2021549227A JP2021549227A JP2022520998A5 JP 2022520998 A5 JP2022520998 A5 JP 2022520998A5 JP 2021549227 A JP2021549227 A JP 2021549227A JP 2021549227 A JP2021549227 A JP 2021549227A JP 2022520998 A5 JP2022520998 A5 JP 2022520998A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
approximately
antialbumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520998A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019215 external-priority patent/WO2020172528A1/en
Publication of JP2022520998A publication Critical patent/JP2022520998A/ja
Publication of JP2022520998A5 publication Critical patent/JP2022520998A5/ja
Pending legal-status Critical Current

Links

JP2021549227A 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用 Pending JP2022520998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809475P 2019-02-22 2019-02-22
US62/809,475 2019-02-22
PCT/US2020/019215 WO2020172528A1 (en) 2019-02-22 2020-02-21 Albumin binding antibodies and use thereof

Publications (2)

Publication Number Publication Date
JP2022520998A JP2022520998A (ja) 2022-04-04
JP2022520998A5 true JP2022520998A5 (cg-RX-API-DMAC7.html) 2023-02-28

Family

ID=72144485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549227A Pending JP2022520998A (ja) 2019-02-22 2020-02-21 アルブミン結合抗体及びその使用

Country Status (6)

Country Link
US (1) US12479909B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927740A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022520998A (cg-RX-API-DMAC7.html)
CN (1) CN113508134B (cg-RX-API-DMAC7.html)
TW (1) TW202045545A (cg-RX-API-DMAC7.html)
WO (1) WO2020172528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3102036A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US12240879B2 (en) 2020-07-30 2025-03-04 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions
EP4192959A4 (en) * 2020-10-02 2024-10-30 Agency for Science, Technology and Research EXPRESSION SYSTEM FOR PROTEIN PRODUCTION AND SCREENING
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
WO2022125566A1 (en) * 2020-12-08 2022-06-16 Janux Therapeutics, Inc. Half-life extending compositions and methods
WO2022257868A1 (zh) * 2021-06-07 2022-12-15 上海济煜医药科技有限公司 抗人血清白蛋白的抗原结合蛋白
JP2025517120A (ja) * 2022-05-05 2025-06-03 インヒブルクス バイオサイエンシズ インコーポレイテッド アルブミン結合ポリペプチド及びその使用
JP2025526875A (ja) * 2022-08-17 2025-08-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 改善された抗アルブミンナノボディおよびその使用
WO2024051796A1 (en) * 2022-09-09 2024-03-14 Wuxi Biologics (Shanghai) Co., Ltd. Albumin binding proteins, fusion proteins and uses thereof
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2024236068A1 (en) * 2023-05-17 2024-11-21 Navigo Proteins Affinity ligand for a single chain antibody fragment specific for serum albumin
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US9156914B2 (en) * 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2740561C (en) 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9556273B2 (en) * 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
CA2808683A1 (en) * 2010-08-20 2012-02-23 Glaxosmithkline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2013110531A1 (en) * 2012-01-23 2013-08-01 Ablynx Nv Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN111548418A (zh) * 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2016034968A1 (en) * 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
EP3221364B1 (en) * 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
HUE057241T2 (hu) * 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CN118126157A (zh) * 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
CA3076250A1 (en) * 2017-10-02 2019-04-11 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
CA3102036A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
US12240879B2 (en) * 2020-07-30 2025-03-04 Anwita Biosciences, Inc. Interleukin-22 fusion proteins, and their pharmaceutical compositions

Similar Documents

Publication Publication Date Title
US20230211006A1 (en) Cysteine linked nanobody dimers
AU2021290305B2 (en) Nanobody dimers linked via C-terminally engineered cysteins
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP2016509014A (ja) 新規の多特異的構成物
US20160009824A1 (en) Tetravalent bispecific antibodies
CA3089653A1 (en) Anti-claudin 18.2 antibodies and uses thereof
CN114341186A (zh) 双特异性抗LRRC15和CD3ε抗体
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2013532968A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2012519492A5 (cg-RX-API-DMAC7.html)
JP2021518761A5 (cg-RX-API-DMAC7.html)
CN115461373A (zh) 密蛋白18.2的抗体及其用途
KR20240135654A (ko) 항-her2/trop2 항체 및 이의 용도
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
JP2022502079A5 (cg-RX-API-DMAC7.html)
US20250019457A1 (en) Trop2 antibodies
KR20250012612A (ko) 고형 종양을 치료하는 방법
CN120554510B (zh) 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物
US20250136694A1 (en) Anti-b7-h4 antibody, and preparation method therefor and use thereof
WO2025021953A1 (en) Antigen-binding molecules capable of binding interferon gamma
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
EP4682172A1 (en) Anti-muc17, anti-cd3 and anti-cd28 trispecific antibody
HK40104915A (en) Multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
HK40128404A (en) Trop2 antibodies